A companion for Lynparza
SALT LAKE CITY—The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx for use as a companion diagnostic test to identify patients with metastatic pancreatic cancer with a germline BRCA mutation and the potential to benefit from Lynparza treatment, Myriad Genetics Inc. announced recently. This makes BRACAnalysis CDx the first and only FDA-approved genetic test for this indication. Just last year, the National Comprehensive Cancer Network (NCCN) updated its oncology guidelines to recommend universal germline BRCA testing for all pancreatic cancer patients.
Nicole Lambert, president of Myriad Oncology, commented in part that “The new FDA approval and recently updated NCCN guidelines support physicians who order testing at the time of diagnosis. The sooner we can identify patients with germline BRCA mutations, the better chance they will have to benefit from precision therapies.”